{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:24:03Z","timestamp":1770999843714,"version":"3.50.1"},"reference-count":69,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,5]]},"abstract":"Object.<\/jats:italic> One of the most frequent genetic abnormalities found in patients with glioblastoma multiforme (GBM) is homozygous deletion of the p16<\/jats:italic> tumor suppressor gene. The authors investigated whether this deletion is associated with prognosis in patients with GBM.<\/jats:p>\nMethods.<\/jats:italic> In 46 adult patients with supratentorial GBM, homozygous deletion of the p16<\/jats:italic> gene in tumor DNA was examined using the multiplex polymerase chain reaction assay. The deletion was confirmed in 14 (30.4%) of 46 patients, eight (30.8%) of 26 men and six (30.0%) of 20 women. Cox proportional hazard regression analysis, adjusted for age at surgery, the Karnofsky Performance Scale score, extent of resection, and the MIB-1 labeling index, revealed that homozygous deletion of the p16<\/jats:italic> gene was significantly associated with overall survival and progression-free survival in men, but not in women.<\/jats:p>\nConclusions.<\/jats:italic> The results of this study suggest that p16<\/jats:italic> homozygous deletion is a significant unfavorable prognostic factor in male patients with GBM.<\/jats:p>","DOI":"10.3171\/jns.2002.96.5.0815","type":"journal-article","created":{"date-parts":[[2009,5,13]],"date-time":"2009-05-13T17:44:41Z","timestamp":1242236681000},"page":"815-822","source":"Crossref","is-referenced-by-count":37,"title":["Analysis of homozygous deletion of the p16 gene and correlation with survival in patients with glioblastoma multiforme"],"prefix":"10.3171","volume":"96","author":[{"given":"Takanori","family":"Kamiryo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Shinojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Kochi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-ichi","family":"Kuratsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Saya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukitaka","family":"Ushio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1754","reference":[{"key":"b1","series-title":"Int J Oncol","first-page":"1111","article-title":"Analysis of cyclin dependent kinase inhibitors in malignant astrocytomas.","volume":"14","author":"Alleyne","year":"1999"},{"key":"b2","series-title":"Cancer Res","first-page":"1351","article-title":"Replacement of the p16\/CDKN2 gene suppresses human glioma cell growth.","volume":"55","author":"Arap","year":"1995"},{"key":"b3","series-title":"J Neurol Neurosurg Psychiatry","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1136\/jnnp.39.3.290","article-title":"Epidemiology of primary tumours of the brain and spinal cord: a regional survey in southern England.","volume":"39","author":"Barker","year":"1976"},{"key":"b4","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1023\/A:1005768910871","article-title":"P16 deletion and mutation analysis in human brain tumors.","volume":"31","author":"Barker","year":"1997"},{"key":"b5","series-title":"Acta Neuropathol","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s004010050711","article-title":"Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas.","volume":"94","author":"Biernat","year":"1997"},{"key":"b6","series-title":"J Neuropathol Exp Neurol","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/00005072-199802000-00003","article-title":"Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas.","volume":"57","author":"Burns","year":"1998"},{"key":"b7","series-title":"J Pathol","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/path.1711680404","article-title":"Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.","volume":"168","author":"Cattoretti","year":"1992"},{"key":"b8","series-title":"Cancer Res","first-page":"2405","article-title":"Silencing of p16\/CDKN2 expression in human gliomas by methylation and chromatin condensation.","volume":"56","author":"Costello","year":"1996"},{"key":"b9","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/jns.1998.88.1.0001","article-title":"Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973\u20131991.","volume":"88","author":"Davis","year":"1998"},{"key":"b10","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3171\/jns.1993.78.5.0767","article-title":"Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome.","volume":"78","author":"Devaux","year":"1993"},{"key":"b11","series-title":"Cancer Res","first-page":"984","article-title":"Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization.","volume":"55","author":"Dreyling","year":"1995"},{"key":"b12","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3171\/jns.1993.78.6.0909","article-title":"A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study.","volume":"78","author":"Eyre","year":"1993"},{"key":"b13","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/(SICI)1097-0142(19970315)79:6<1195::AID-CNCR19>3.0.CO;2-V","article-title":"Descriptive epidemiology of cerebral gliomas in France.","volume":"79","author":"Fleury","year":"1997"},{"key":"b14","series-title":"Oncogene","first-page":"1615","article-title":"Hypermethylation of the CpG island of p16\/CDKN2 correlates with gene inactivation in gliomas.","volume":"13","author":"Fueyo","year":"1996"},{"key":"b15","series-title":"Oncogene","first-page":"103","article-title":"Adenovirus-mediated p16\/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells.","volume":"12","author":"Fueyo","year":"1996"},{"key":"b16","series-title":"Oncogene","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1038\/sj.onc.1203700","article-title":"p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma.","volume":"19","author":"Fulci","year":"2000"},{"key":"b17","series-title":"Cancer Res","first-page":"6338","article-title":"Mutation rate of the CDKN2 gene in malignant gliomas.","volume":"54","author":"Giani","year":"1994"},{"key":"b18","series-title":"Cancer Res","first-page":"5804","article-title":"CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines.","volume":"54","author":"He","year":"1994"},{"key":"b19","series-title":"Int J Cancer","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/(SICI)1097-0215(19970926)73:1<57::AID-IJC10>3.0.CO;2-2","article-title":"Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas.","volume":"73","author":"Hegi","year":"1997"},{"key":"b20","series-title":"Am J Clin Pathol","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/ajcp\/75.6.816","article-title":"The use of antiavidin antibody and avidin-biotin peroxidase complex in immunoperoxidase technics.","volume":"75","author":"Hsu","year":"1981"},{"key":"b21","series-title":"Cancer Res","first-page":"417","article-title":"Deregulation of the p14ARF\/MDM2\/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.","volume":"60","author":"Ichimura","year":"2000"},{"key":"b22","series-title":"Oncogene","first-page":"1065","article-title":"Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene.","volume":"13","author":"Ichimura","year":"1996"},{"key":"b23","series-title":"Ann Neurol","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1002\/ana.410280614","article-title":"Effects of treatment on long-term survivors with malignant astrocytomas.","volume":"28","author":"Imperato","year":"1990"},{"key":"b24","series-title":"Int J Oncol","first-page":"547","article-title":"Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluation.","volume":"15","author":"James","year":"1999"},{"key":"b25","series-title":"Cancer Res","first-page":"6353","article-title":"Deletion of p16 and p15 genes in brain tumors.","volume":"54","author":"Jen","year":"1994"},{"key":"b26","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/1097-0142(19910915)68:6<1394::AID-CNCR2820680636>3.0.CO;2-8","article-title":"A population-based study on the incidence and survival rates of 3857 glioma patients diagnosed from 1953 to 1984.","volume":"68","author":"Kallio","year":"1991"},{"key":"b27","series-title":"Science","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1126\/science.8153634","article-title":"A cell cycle regulator potentially involved in genesis of many tumor types.","volume":"264","author":"Kamb","year":"1994"},{"key":"b28","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1023\/A:1006473320474","article-title":"Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and prb, and Ki-67 labeling in high grade astrocytomas treated with radiotherapy.","volume":"46","author":"Kirla","year":"2000"},{"key":"b29","series-title":"Histological Typing of Tumours of the Central Nervous System.","author":"Kleihues","year":"1993"},{"key":"b30","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1023\/A:1006457502972","article-title":"Randomized comparison of intra-arterial versus intravenous infusion of ACNU for newly diagnosed patients with glioblastoma.","volume":"49","author":"Kochii","year":"2000"},{"key":"b31","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1023\/A:1006402614838","article-title":"Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme.","volume":"48","author":"Kraus","year":"2000"},{"key":"b32","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"946","DOI":"10.3171\/jns.1996.84.6.0946","article-title":"Epidemiological study of primary intracranial tumors: a regional survey in Kumamoto Prefecture in the southern part of Japan.","volume":"84","author":"Kuratsu","year":"1996"},{"key":"b33","series-title":"Oncogene","first-page":"63","article-title":"Mutations of the p16 gene in gliomas.","volume":"12","author":"Kyritsis","year":"1996"},{"key":"b34","series-title":"Oncogene","first-page":"597","article-title":"Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas.","volume":"11","author":"Li","year":"1995"},{"key":"b35","series-title":"Clin Neuropharmacol","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/00002826-198412000-00011","article-title":"Estrogen and progesterone receptors in intracranial tumors.","volume":"7","author":"Martinez","year":"1984"},{"key":"b36","series-title":"J Neuropathol Exp Neurol","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1097\/00005072-199756070-00006","article-title":"A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters.","volume":"56","author":"McKeever","year":"1997"},{"key":"b37","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3171\/jns.2000.93.6.0932","article-title":"The impact of age and sex on the incidence of glial tumors in New York state from 1976 to 1995.","volume":"93","author":"McKinley","year":"2000"},{"key":"b38","series-title":"Nat Med","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/nm0795-686","article-title":"5\u2032 CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16\/CDKN2\/MTS1 in human cancers.","volume":"1","author":"Merlo","year":"1995"},{"key":"b39","series-title":"Int J Oncol","first-page":"983","article-title":"Homozygous deletion of the p16\/MTS-1\/CDKN2 gene in malignant gliomas is infrequent among Japanese patients.","volume":"15","author":"Mochizuki","year":"1999"},{"key":"b40","series-title":"Neurosurgery","first-page":"674","article-title":"Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms.","volume":"34","author":"Montine","year":"1994"},{"key":"b41","series-title":"Am J Pathol","first-page":"613","article-title":"MTS1\/p16\/CDKN2 lesions in primary glioblastoma multiforme.","volume":"146","author":"Moulton","year":"1995"},{"key":"b42","series-title":"Int J Oncol","first-page":"889","article-title":"Immunohistochemical detection of CDKN2, retinoblastoma and p53 gene products in primary astrocytic tumors.","volume":"8","author":"Nakamura","year":"1996"},{"key":"b43","series-title":"Hum Pathol","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0046-8177(00)80207-5","article-title":"Incidence of p14ARF gene deletion in high-grade adult and pediatric astrocytomas.","volume":"31","author":"Newcomb","year":"2000"},{"key":"b44","series-title":"Brain Pathol","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1750-3639.1998.tb00191.x","article-title":"Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes.","volume":"8","author":"Newcomb","year":"1998"},{"key":"b45","series-title":"Nature","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/368753a0","article-title":"Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.","volume":"368","author":"Nobori","year":"1994"},{"key":"b46","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/1097-0142(19900701)66:1<6::AID-CNCR2820660103>3.0.CO;2-F","article-title":"Low-grade cerebral astrocytomas. Survival and quality of life after radiation therapy.","volume":"66","author":"North","year":"1990"},{"key":"b47","series-title":"J Natl Cancer Inst","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/jnci\/90.4.307","article-title":"Molecular detection of cancer cells by competitive reverse transcription-polymerase chain reaction analysis of specific CD44 variant RNAs.","volume":"90","author":"Okamoto","year":"1998"},{"key":"b48","series-title":"J Neuropathol Exp Neurol","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1097\/00005072-199655100-00002","article-title":"Malignant astrocytomas with homozygous CDKN2\/p16 gene deletions have higher Ki-67 proliferation indices.","volume":"55","author":"Ono","year":"1996"},{"key":"b49","series-title":"Am J Clin Pathol","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1093\/ajcp\/112.6.801","article-title":"Detection of p16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas.","volume":"112","author":"Perry","year":"1999"},{"key":"b50","series-title":"J Neuropathol Exp Neurol","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1097\/00005072-199709000-00005","article-title":"Detection of p16 gene deletions in gliomas: a comparison of fluorescence in situ hybridization (FISH) versus quantitative PCR.","volume":"56","author":"Perry","year":"1997"},{"key":"b51","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.3171\/jns.1999.90.6.1072","article-title":"Hormonal effects on glioblastoma multiforme in the nude rat model.","volume":"90","author":"Plunkett","year":"1999"},{"key":"b52","series-title":"Int J Oncol","first-page":"963","article-title":"Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival.","volume":"17","author":"Puduvalli","year":"2000"},{"key":"b53","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3171\/jns.1960.17.4.0736","article-title":"Glioblastoma multiforme: a clinical survey.","volume":"17","author":"Roth","year":"1960"},{"key":"b54","series-title":"Neurosurgery","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1227\/00006123-199402000-00002","article-title":"Long-term survival in patients with malignant astrocytoma.","volume":"34","author":"Salcman","year":"1994"},{"key":"b55","series-title":"J Pathol","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/path.1711740407","article-title":"Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples.","volume":"174","author":"Sallinen","year":"1994"},{"key":"b56","series-title":"Neurosurgery","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/00006123-197909000-00001","article-title":"Radiotherapy of intracranial astrocytomas: analysis of 417 cases treated from 1960 through 1969.","volume":"5","author":"Scanlon","year":"1979"},{"key":"b57","series-title":"J Natl Cancer Inst","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/jnci\/84.17.1346","article-title":"Association between brain tumors and menopausal status.","volume":"84","author":"Schlehofer","year":"1992"},{"key":"b58","series-title":"Br J Cancer","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/bjc.1997.2","article-title":"Infrequent methylation of CDKN2A(MTS1\/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2\/p15) in primary astrocytic tumours.","volume":"75","author":"Schmidt","year":"1997"},{"key":"b59","series-title":"Cancer Res","first-page":"6321","article-title":"CDKN2 (p16\/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.","volume":"54","author":"Schmidt","year":"1994"},{"key":"b60","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/jns.1989.71.1.0001","article-title":"Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001.","volume":"71","author":"Shapiro","year":"1989"},{"key":"b61","series-title":"Oncogene","first-page":"2145","article-title":"Homozygous deletion of the MTS1\/p16 and MTS2\/p15 genes and amplification of the CDK4 gene in glioma.","volume":"11","author":"Sonoda","year":"1995"},{"key":"b62","series-title":"Hum Pathol","first-page":"263","article-title":"Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques.","volume":"25","author":"Taylor","year":"1994"},{"key":"b63","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/(SICI)1097-0142(19960715)78:2<287::AID-CNCR15>3.0.CO;2-S","article-title":"Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.","volume":"78","author":"Tsuzuki","year":"1996"},{"key":"b64","series-title":"Cancer Res","first-page":"150","article-title":"CDKN2\/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.","volume":"56","author":"Ueki","year":"1996"},{"key":"b65","series-title":"Hum Mol Genet","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1093\/hmg\/3.10.1841","article-title":"MTS1\/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p.","volume":"3","author":"Ueki","year":"1994"},{"key":"b66","series-title":"Surg Neurol","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/0090-3019(92)90022-F","article-title":"Long-term survival after the diagnosis of malignant glioma: a series of 22 patients surviving more than 4 years after diagnosis.","volume":"38","author":"Vertosick","year":"1992"},{"key":"b67","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<373::AID-CNCR21>3.0.CO;2-Y","article-title":"Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas.","volume":"77","author":"Wakimoto","year":"1996"},{"key":"b68","series-title":"Neurology","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1212\/WNL.35.2.219","article-title":"Epidemiology of brain tumors: the national survey of intracranial neoplasms.","volume":"35","author":"Walker","year":"1985"},{"key":"b69","series-title":"Cancer Res","first-page":"20","article-title":"Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas.","volume":"55","author":"Walker","year":"1995"}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/96\/5\/article-p815.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/96\/5\/article-p815.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/96\/5\/article-p815.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T21:46:04Z","timestamp":1679867164000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/96\/5\/article-p815.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":69,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.3171\/jns.2002.96.5.0815","relation":{},"ISSN":["0022-3085"],"issn-type":[{"value":"0022-3085","type":"print"}],"subject":[],"published":{"date-parts":[[2002,5]]}}}